Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.
J Drug Target. 2020 Jan;28(1):11-22. doi: 10.1080/1061186X.2019.1587444. Epub 2019 Jul 22.
Neuropathic pain (NeP) is a complex chronic pain condition associated with nerve injury. Approximately, 7-10% of the general population across the globe is suffering from this traumatic condition, but the existing treatment strategies are inadequate to deliver pain relief and are associated with severe adverse effects. To overcome these limitations, lot of research is focussed on developing new molecules with high potency and fewer side effects, novel cell and gene-based therapies and modification of the previously approved drugs by different formulation aspects. Nanomedicine has attracted a lot of attention in the treatment of many diverse pathological conditions because of their unique physiochemical and biological properties. In this manuscript, we highlighted the emerging role of nanomedicine in different therapies (drug, cell and gene), also we emphasised on the challenges associated with nanomedicine such as development of well-characterised nanoformulation, scaling of batches with reproducible results and toxicity along with this we discussed about the future of nanomedicine in the treatment of neuropathic pain.
神经病理性疼痛(NeP)是一种与神经损伤相关的复杂慢性疼痛病症。全球大约有 7-10%的普通人群患有这种创伤性疾病,但现有的治疗策略不足以缓解疼痛,并且还伴随着严重的不良反应。为了克服这些局限性,许多研究都集中在开发具有高效力和更少副作用的新型分子、新型细胞和基因治疗方法,以及通过不同的制剂方面来改变已批准药物。由于纳米医学具有独特的物理化学和生物学特性,因此在治疗许多不同的病理状况方面引起了广泛关注。在本文中,我们强调了纳米医学在不同治疗方法(药物、细胞和基因)中的新兴作用,还强调了与纳米医学相关的挑战,例如开发具有良好特征的纳米制剂、具有可重复结果的批量放大以及毒性,同时还讨论了纳米医学在治疗神经病理性疼痛方面的未来。